Oncology

WHO Clears Celltrion Rituximab for Use

June 8th 2020

By Tony Hagen

As part of pilot program designed to improve access to cheaper medications in oncology, a rituximab biosimilar from Celltrion has been approved for use by the World Health Organization (WHO).

Timeline Is Extended for Practices Struggling With COVID-19

June 4th 2020

By Tony Hagen

Article

Recognizing that oncology practices are struggling with the pandemic, the Center for Medicare and Medicaid Innovation has eased some performance requirements.

ASCO20 Virtual Biosimilars Roundup

June 3rd 2020

By Skylar Jeremias

Video

Here is a summary of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).

Clinically Meaningful Differences Under the Microscope

June 3rd 2020

By Skylar Jeremias

Article

Clinical trials leading up to biosimilar approval may not reveal the full safety and efficacy profile of biosimilars vs reference products, and postmarketing studies may be essential to elucidate any differences, investigators said.

More Savings Are Possible for Oncology Care Model, ASCO Study Says

June 2nd 2020

By Tony Hagen

Article

A real-world study helped show how pegfilgrastim biosimilar can improve savings in the Oncology Care Model and its successor, the Oncology Care First Model, according to findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Biosimilar Pegfilgrastim Savings Aid More Patients in Models Presented at ASCO

June 1st 2020

By Skylar Jeremias

Article

Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Henlius Receives CHMP Nod for Trastuzumab Biosimilar

June 1st 2020

By Tony Hagen

Article

Shanghai Henlius Biotech received a positive European review opinion for its trastuzumab biosimilar HLXO2 and anticipates marketing authorization in 2 to 3 months.

Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study

May 31st 2020

By Skylar Jeremias

Article

When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Rituximab Biosimilar Demonstrates Similarity in ASCO Study

May 31st 2020

By Tony Hagen

Article

The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

US Needs Drug Negotiating Power, ASCO Study Concludes

May 31st 2020

By Skylar Jeremias

Article

Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation at the American Society of Clinical Oncology.